Top 5 Articles From the Print Publication in 2023
Articles about upcoming approvals and Humira biosimilars were among those that garnered the most interest.
Articles about upcoming approvals and Humira biosimilars were among those that garnered the most interest.
Here are the five articles published in the print publication of Managed Healthcare Executive that had the most pageviews when they were posted on the MHE website.
4 Important Approvals Expected This Year
The approval of Mounjaro (tirzepatide) for weight loss could be a tipping point for weight-loss drugs. [The weight-loss version of tirzepatide is being sold under the brand-name Zepbound.]
’Tis the Year of the Humira Biosimilars
As many as 10 Humira biosimilars [it wound up being just 8] may be on the U.S. market before 2023 is over. AbbVie has taken several steps to protect its revenues, including the launches of Skyrizi and Rinvoq.
The List of PBM Formulary Exclusions Got Longer in 2023
Pharmacy benefit managers say they exclude high-cost drugs and have alternatives on their formularies. Critics say exclusions narrow patient options and may put effective medication financially out of reach.
Why States Are Allowing Pharmacies to Dispense Returned Oncology Drugs
Repositories of donated drugs in 13 states are redistributing oncology medications to those in need.
Antibody-Drug Conjugates Find and Kill Cancer Cells
Three ADCs are in late-stage trials as treatments for patients with non-small cell lung cancer.
Breaking Down Health Plans, HSAs, AI With Paul Fronstin of EBRI
November 19th 2024Featured in this latest episode of Tuning In to the C-Suite podcast is Paul Fronstin, director of health benefits research at EBRI, who shed light on the evolving landscape of health benefits with editors of Managed Healthcare Executive.
Listen
In this latest episode of Tuning In to the C-Suite podcast, Briana Contreras, an editor with MHE had the pleasure of meeting Loren McCaghy, director of consulting, health and consumer engagement and product insight at Accenture, to discuss the organization's latest report on U.S. consumers switching healthcare providers and insurance payers.
Listen
New PTSD Treatment Shows Promise with Brexpiprazole, Sertraline Combination
December 24th 2024Currently, the only medications approved by the FDA for PTSD are the selective serotonin reuptake inhibitors (SSRIs) sertraline and paroxetine. However, these medications don’t work for everyone.
Read More
